Assessment of response
tumor, Pain, pain, prostate cancer tumor, Cancer
CANCER, DISEASE, TUMOR
Radiologic responses were assessed by internal expert review. MRI and PET/CT images were evaluated according to the RECISTv1.1. criteria [Prostate-specific antigen (PSA) levels should change at least 25% and display an absolute increase/decrease of 2 ng/mL to define PSA-related progression or improved disease status [Lactate dehydrogenase (LDH) and alkaline phosphatase (ALP), blood-based markers of prostate cancer tumor load and skeletal involvement, were measured sequentially at the routine laboratory.Circulating tumor cells (CTCs) were enumerated pre-treatment and during all follow-up visits using the CellSearch® System (Menarini Silicon Biosystems) according to the producer's standardized procedure (Supplementary S8). CTC responses were grouped as CTCs = 0 or CTCs > 0 independent of pre-treatment values. The response was estimated for two time points: at first available CTCs measurements after the CryoIT, and two weeks after treatment.Patient-reported outcomes were collected using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire [Pain was evaluated by VAS pain logs prior to treatment, and from week two after CryoIT (Supplementary S6).